Debt-to-equity of Avalo Therapeutics, Inc. from 30 Jun 2016 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Avalo Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2016 to 30 Sep 2025.
  • Avalo Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 20%.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Avalo Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 20% +454% 30 Sep 2025
Q2 2025 34% +383% 30 Jun 2025
Q1 2025 84% +375% 31 Mar 2025
Q4 2024 1533% +370% +32% 31 Dec 2024
Q3 2024 -434% +968% +69% 30 Sep 2024
Q2 2024 -349% +249% +42% 30 Jun 2024
Q1 2024 -292% +358% +55% 31 Mar 2024
Q4 2023 1164% +2570% 31 Dec 2023
Q3 2023 -1402% -2285% -259% 30 Sep 2023
Q2 2023 -598% -921% -285% 30 Jun 2023
Q1 2023 -650% -880% -382% 31 Mar 2023
Q4 2022 -1407% -1563% -999% 31 Dec 2022
Q3 2022 883% +761% +619% 30 Sep 2022
Q2 2022 323% +227% +238% 30 Jun 2022
Q1 2022 230% +170% +281% 31 Mar 2022
Q4 2021 156% +101% +183% 31 Dec 2021
Q3 2021 123% +69% +129% 30 Sep 2021
Q2 2021 95% +16% +21% 30 Jun 2021
Q1 2021 60% -78% -57% 31 Mar 2021
Q4 2020 55% -129% -70% 31 Dec 2020
Q3 2020 54% -174% -76% 30 Sep 2020
Q2 2020 79% -156% -66% 30 Jun 2020
Q1 2020 139% -93% -40% 31 Mar 2020
Q4 2019 185% -30% -14% 31 Dec 2019
Q3 2019 228% +67% +41% 30 Sep 2019
Q2 2019 235% +124% +111% 30 Jun 2019
Q1 2019 232% +149% +179% 31 Mar 2019
Q4 2018 215% +162% +306% 31 Dec 2018
Q3 2018 161% +87% +117% 30 Sep 2018
Q2 2018 112% -501% -82% 30 Jun 2018
Q1 2018 83% -357% -81% 31 Mar 2018
Q4 2017 53% -145% -73% 31 Dec 2017
Q3 2017 74% -44% -37% 30 Sep 2017
Q2 2017 612% +1255% 30 Jun 2017
Q1 2017 440% 31 Mar 2017
Q4 2016 198% 31 Dec 2016
Q3 2016 118% 30 Sep 2016
Q2 2016 -643% 30 Jun 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.